DST results in nonpsychotic depressed outpatients. 1988

A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle.

In two studies using the dexamethasone suppression test (DST) to evaluate the efficacy of newer antidepressants in depressed outpatients, the authors found a DST nonsuppression rate of 13% (11 of 86 patients). Thirty-three of the DST suppressors received an antidepressant and 42 received placebo; the drug-treated group showed a significant therapeutic response. The low rate of DST nonsuppression in these depressed outpatients, a finding consistent with that of other investigators, does not confirm or refute reports that these patients are relatively resistant to placebo in comparison with active medication. The authors recommend that DST results not be used as selection criteria in studies assessing newer therapies for depressed outpatients.

UI MeSH Term Description Entries
D008297 Male Males
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
January 1986, International clinical psychopharmacology,
A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
August 1985, The American journal of psychiatry,
A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
January 1988, Journal of neural transmission,
A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
February 2004, The Journal of clinical psychiatry,
A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
September 1989, Pharmacopsychiatry,
A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
February 2005, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
August 1990, Journal of consulting and clinical psychology,
A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
June 1982, The American journal of psychiatry,
A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
January 1991, Psychopharmacology bulletin,
A Khan, and F Johnson, and D H Avery, and S Cohen, and B Scherzo, and D L Dunner
September 2007, Journal of attention disorders,
Copied contents to your clipboard!